Your browser doesn't support javascript.
loading
Targeting progesterone signaling prevents metastatic ovarian cancer.
Kim, Olga; Park, Eun Young; Kwon, Sun Young; Shin, Sojin; Emerson, Robert E; Shin, Yong-Hyun; DeMayo, Francesco J; Lydon, John P; Coffey, Donna M; Hawkins, Shannon M; Quilliam, Lawrence A; Cheon, Dong-Joo; Fernández, Facundo M; Nephew, Kenneth P; Karpf, Adam R; Widschwendter, Martin; Sood, Anil K; Bast, Robert C; Godwin, Andrew K; Miller, Kathy D; Cho, Chi-Heum; Kim, Jaeyeon.
Afiliación
  • Kim O; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202.
  • Park EY; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202.
  • Kwon SY; Department of Pathology, School of Medicine, Keimyung University, 41931 Daegu, Republic of Korea.
  • Shin S; Department of Obstetrics and Gynecology, School of Medicine, Keimyung University, 41931 Daegu, Republic of Korea.
  • Emerson RE; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.
  • Shin YH; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202.
  • DeMayo FJ; Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709.
  • Lydon JP; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX 77030.
  • Coffey DM; Department of Pathology and Genomic Medicine, Houston Methodist and Weill Cornell Medical College, Houston, TX 77030.
  • Hawkins SM; Department of Obstetrics and Gynecology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202.
  • Quilliam LA; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202.
  • Cheon DJ; Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, NY 12208.
  • Fernández FM; School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332.
  • Nephew KP; Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN 47405.
  • Karpf AR; Eppley Institute for Cancer Research, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198.
  • Widschwendter M; Department of Women's Cancer, Institute for Women's Health, University College London, WC1E 6AU London, United Kingdom.
  • Sood AK; Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020 Innsbruck, Austria.
  • Bast RC; European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, 6060 Hall in Tirol, Austria.
  • Godwin AK; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Miller KD; Department of Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Cho CH; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Kim J; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160.
Proc Natl Acad Sci U S A ; 117(50): 31993-32004, 2020 12 15.
Article en En | MEDLINE | ID: mdl-33262282
Effective cancer prevention requires the discovery and intervention of a factor critical to cancer development. Here we show that ovarian progesterone is a crucial endogenous factor inducing the development of primary tumors progressing to metastatic ovarian cancer in a mouse model of high-grade serous carcinoma (HGSC), the most common and deadliest ovarian cancer type. Blocking progesterone signaling by the pharmacologic inhibitor mifepristone or by genetic deletion of the progesterone receptor (PR) effectively suppressed HGSC development and its peritoneal metastases. Strikingly, mifepristone treatment profoundly improved mouse survival (∼18 human years). Hence, targeting progesterone/PR signaling could offer an effective chemopreventive strategy, particularly in high-risk populations of women carrying a deleterious mutation in the BRCA gene.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Progesterona / Mifepristona / Cistadenocarcinoma Seroso / Proteína BRCA1 Tipo de estudio: Prognostic_studies Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Progesterona / Mifepristona / Cistadenocarcinoma Seroso / Proteína BRCA1 Tipo de estudio: Prognostic_studies Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article